Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FATE vs VCYT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
VCYT Overall Winner
6-Pillar Tally: FATE 1 – 5 VCYT
Matrix Metrics: FATE 2 – 8 VCYT
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FATE carries a Unified Composite Score of 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).
- Technical & Structure Timing Caution: FATE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FATE vs VCYT
FATE
Fate Therapeutics, Inc.
$1.14
-10.94% 1D
Market Cap
$155.7M
TTM Revenue
$4.8M
Forward P/E
N/M
Beta / 30D Vol
2.16β · 104% Vol
Unified Composite Score
43.0
HOLD
Tech 25.0
Fund 47.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
VCYT
Head-to-Head Winner
Veracyte, Inc.
$24.01
-1.32% 1D
Market Cap
$2.0B
TTM Revenue
$582M
Forward P/E
15.3x
Beta / 30D Vol
3.01β · 199% Vol
Unified Composite Score
49.1
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (FATE 1 – 5 VCYT)
1. Valuation Multiples
VCYT
Forward P/E
N/M
15.3x
Trailing P/E
N/M
15.8x
PEG Ratio
N/M
N/M
EV / Revenue
39.2x
3.1x
2. Growth & Scale
VCYT
Revenue Growth (YoY)
+9.2%
+15.1%
Earnings Growth (YoY)
+0.0%
+58.3%
TTM Revenue (USD)
$4.8M
$582M
Market Cap
$155.7M
$2.0B
3. Profitability & Quality
VCYT
Gross Margin
N/A
74.2%
Operating Margin
-2736.9%
15.0%
Net Profit Margin
0.0%
21.8%
Return on Equity (ROE)
-67.8%
9.4%
4. Balance Sheet & Cash Flow
VCYT
Cash Generation (TTM)
-$107M
$162M
Cash Flow Margin
N/A
27.8%
Net Cash / Leverage
$31M Net Debt (0.56x D/E)
$159M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FATE
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
169.0% (20th %ile)
197.3% (47th %ile)
Put/Call OI Skew
1.52x (Put-Skewed)
0.01x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
VCYT
OpEx & R&D Intensity
N/A
59.2% of Rev ($344M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FATE (2) vs VCYT (8)| Institutional Metric | FATE | VCYT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $155.7M | $2.0B | VCYT | |
| Trailing P/E Ratio | N/M | 15.8x | VCYT | |
| Forward P/E Ratio | N/M | 15.3x | VCYT | |
| Revenue Growth (YoY) | +9.2% | +15.1% | VCYT | |
| Operating Margin (TTM) | -2736.9% | 15.0% | VCYT | |
| Net Profit Margin | 0.0% | 21.8% | VCYT | |
| Return on Equity (ROE) | -67.8% | 9.4% | VCYT | |
| 52-Week Range Position | 8% ($1–$3) | 5% ($22–$61) | FATE | |
| Beta / 30D Volatility | 2.16β · 104% Vol | 3.01β · 199% Vol | FATE | |
| Unified Institutional Score | 43.0 / 100 (HOLD) | 49.1 / 100 (HOLD) | VCYT | |
| Trailing 12M Revenue (USD) | $4.8M | $582M | Scale | |
| Gross Profit Margin (TTM) | N/A | 74.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 39.2x EV/Rev | N/M PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$107M ($31M Net Debt (0.56x D/E)) | $162M ($159M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
FATE +8.01 pp
3M Horizon
VCYT +14.49 pp
6M Horizon
FATE +8.04 pp
1Y Horizon
FATE +54.66 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FATE Revenue | VCYT Revenue | FATE Op. Margin | VCYT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $90M | -1415.4% | -24.2% | VCYT |
| FY2019 | $10M | $120M | -943.1% | -12.6% | VCYT |
| FY2020 | $30M | $120M | -407.5% | -30.1% | VCYT |
| FY2021 | $60M | $220M | -388.6% | -37.3% | VCYT |
| FY2022 | $100M | $300M | -320.2% | -13.9% | VCYT |
| FY2023 | $60M | $360M | -299.9% | -23.8% | VCYT |
| FY2024 | $10M | $450M | -1542.6% | 3.6% | VCYT |
| FY2025 | $10M | $520M | -2222.4% | 11.2% | VCYT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FATE
BREAKDOWN
Current IV
169.0%
IV Percentile
20th %ile
Put/Call OI Skew
1.52x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact FATE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
VCYT
BREAKDOWN
Current IV
197.3%
IV Percentile
47th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FATE Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
VCYT Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
59.2% of Rev ($344M)
90D Engineering Disclosures
0 Published
Investor FAQ FATE vs VCYT Key Questions & Quantitative Answers
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FATE carries a Unified Composite Score of 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: FATE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCYT leads the Growth & Scale pillar: FATE posts +9.2% YoY revenue growth and +0.0% YoY earnings growth on $4.8M TTM revenue (N/A gross margin, -2736.9% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FATE cumulative revenue shifted +0.0% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, FATE deploys N/A (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.
VCYT screens cheaper on headline valuation multiples. FATE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 39.2x EV/Revenue (unreported FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FATE (-67.8% ROE) versus VCYT (9.4% ROE) capital efficiency.
In options market volatility and institutional positioning, FATE carries 169.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.52x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 104% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
VCYT vs FATE · Reverse Pair
FATE vs BEAM
· Sector Peer
FATE vs TWST
· Sector Peer
FATE vs IOVA
· Sector Peer
VCYT vs CDNA
· Sector Peer
VCYT vs TWST
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem